Lyso‐phosphatidylcholine: A potential metabolomic biomarker for alcoholic liver disease?

Ştefănescu, Horia; Suciu, A; Romanciuc, Florina; Crişan, Dana; Procopeţ, Bogdan; Radu, Corina; Tanţău, Marcel; Socaciu, Carmen; Grigorescu, Mircea

doi:10.1002/hep.28630

Cited by 9 publications

(11 citation statements)

References 4 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urinary indole-3-acetic acid has been identified as a potential biomarker for early alcoholic liver disease on animal model, by two studies performed by LC-MS[ 30 , 31 ]. Our group, in a pilot study, proved that lysophosphatidylcholine (LPC) 16:1 and 20:4 decease progressively with the severity of alcoholic liver disease and this is correlated with survival and the occurrence of liver related events[ 32 ]. However, if these metabolic changes are rather general in ACLD or specific to alcoholic liver disease remains to be proved.…”

Section: Metabolomics and Alcoholic Liver Diseasementioning

confidence: 99%

Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease

Procopeţ¹,

Fischer²,

Farcau³

et al. 2018

WJH

Self Cite

View full text Add to dashboard Cite

Currently there is a lack of accurate biomarkers for diagnosis and prognosis in advanced liver diseases. Either the occurrence of first decompensation, or diagnosis of acute on chronic liver failure, severe alcoholic hepatitis, or hepatocellular carcinoma (HCC), none of the available biomarkers are satisfactory. Metabolomics is the newest of omics, being much closer than the others to the actual phenotype and pathologic changes that characterizes a certain condition. It deals with a much wider spectrum of low molecular weight bio-compounds providing a powerful platform for discovering novel biomarkers and biochemical pathways to improve diagnostic, prognostication and therapy. Until now metabolomics was applied in a wide spectrum of liver conditions, but the findings were contradictory. This review proposes a synthesis of the existing evidences of metabolomics use in advanced chronic liver diseases, decompensated liver cirrhosis, severe alcoholic hepatitis and HCC.

show abstract

Section: Metabolomics and Alcoholic Liver Diseasementioning

confidence: 99%

Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease

Procopeţ¹,

Fischer²,

Farcau³

et al. 2018

WJH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Phosphatidylcholine (PC) is a ubiquitous membrane phospholipid that is essential for cellular differentiation, proliferation, and regeneration and is necessary for the transport of molecules through membranes [6]. It has been recognized as a marker of liver diseases [7]. Levels of PC in both serum and liver tissue are markedly decreased in liver cirrhosis [8, 9].…”

Section: Introductionmentioning

confidence: 99%

Oral Phosphatidylcholine Improves Intestinal Barrier Function in Drug-Induced Liver Injury in Rats

Chen

Huang

Zhou

et al. 2019

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Objective. Phosphatidylcholine (PC) is the major surface-active phospholipid and creates a hydrophobic nature to the surface. It has been reported to reverse the progression of liver fibrosis and to improve liver function. The aim of the present study was to evaluate the effects of orally administered PC on intestinal barrier function (IBF) in rats with drug-induced liver injury. Method. Rats with carbon tetrachloride- (CCl4-) induced liver injury were treated with 100 mg/kg PC once daily for 21 days. The effects of PC therapy on (i) liver function and portal pressure, (ii) intestinal and hepatic histology, and (iii) plasma endotoxin, diamine oxidase (DAO), and tumour necrosis factor- (TNF-) α levels were investigated. Results. PC therapy reduced portal pressure and improved the liver function in CCl4-induced liver injury. In PC-treated liver injury rats, collagen fibres were gradually decreased, while the disordered arrangement of hepatocytes and disorganized hepatic lobules were partially repaired, and inflammatory cell infiltration was decreased in the fibrous tissue. Lower inflammatory cell infiltration in the ileum improved intestinal histology, and reduced serum DAO levels were observed in PC-treated cirrhotic rats. These changes were associated with reduced inflammatory activity, as indicated by decreased serum TNF-α levels and plasma endotoxin levels. Conclusions. These results suggest that PC therapy is hepatoprotective and is able to restore IBF and reduce endotoxaemia in rats with drug-induced liver injury.

show abstract

“…In this respect, Li et al [19] found in a murine model that metabolites of phosphatidyl choline, sphyngomielin as well as some aminoacids were associated with the development of hepatocellular carcinoma in ALD [19]. Our group previously identified an isoform of LPC to be a good predictor of liver related decompensation and death in patients with severe AH [33]. Similarly, all the relevant metabolites identified by this study using an untargeted approach are also related with the lipid pathway, demonstrating the importance of this pathway in the development and progression of ALD.…”

Section: Discussionmentioning

confidence: 92%

“…By using different methods to purify the metabolites' signature obtained from patients with ALD, we identified 5 serum and 1 urine metabolites, of which one (NLG) seemed accurate for identifying cirrhotic patients and another (DTEA) appeared to be more appropriate to select patients with severe disease. Multiple studies have analyzed the metabolomics profile for other hepatic diseases such as nonalcoholic fatty liver disease (NAFLD), viral hepatitis and hepatocellular carcinoma [24][25][26][27][28][29][30][31][32][33], trying to identify possible biomarkers for disease progression. In NAFLD, elevated hepatic concentrations of various lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE) and phosphatidylcholine (PC) species have been reported for human steatotic vs. nonsteatotic livers [24,30].…”

Section: Discussionmentioning

confidence: 99%

What’s in Metabolomics for Alcoholic Liver Disease?

Suciu

Crişan

Procopeţ

et al. 2018

JGLD

Self Cite

View full text Add to dashboard Cite

show abstract

Lyso‐phosphatidylcholine: A potential metabolomic biomarker for alcoholic liver disease?

Cited by 9 publications

References 4 publications

Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease

Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease

Oral Phosphatidylcholine Improves Intestinal Barrier Function in Drug-Induced Liver Injury in Rats

What’s in Metabolomics for Alcoholic Liver Disease?

Contact Info

Product

Resources

About